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The feline immunodeficiency virus (FIV) is a recently identified feline lentivirus that has been found at
significant levels in domestic cat populations worldwide. A microdilution plate format, monoclonal antibody-
based enzyme-linked immunosorbent assay was developed for the detection of the FIV group-associated antigen
(gag) designated p24. Assays of serially diluted samples containing disrupted virus showed that the assay had
a sensitivity limit of approximately 0.2 ng/ml for FIV p24. The assay was approximately eightfold more
sensitive than the assay for viral reverse transcriptase activity when it was tested with diluted tissue culture
samples. A qualitative confirmation assay by standard antibody inhibition techniques was coupled to the
screening test methodology. The test was used to detect and confirm the presence of virus in cultured feline
lymphocytes from infected animals.
The feline immunodeficiency virus (FIV), formerly feline
T-lymphotropic lentivirus, is a feline retrovirus that can
produce chronic immunodeficiency-like disorders in cats
(21, 22). The FIV agent has a strong, but not absolute,
tropism for the feline T-lymphocyte cell line, which may be
responsible for the immunosuppressive nature of the virus.
The virus has been classified as a lentivirus based on the
morphology of the viral particle and the Mg2+ requirement
of the viral reverse transcriptase (9, 24, 29). The virus
represents the initial description of a feline lentivirus (22).
Members of the lentivirus subfamily that infect other species
include the human immunodeficiency viruses (5, 15), simian
immunodeficiency virus (1), visna virus (18), caprine arthri-
tis-encephalitis virus (4), equine infectious anemia virus (20),
and bovine immunodeficiency-like virus (6).
FIV is infectious within domestic cat populations and has
been transmitted following prolonged contact (22). FIV
infection has been reported in the United States, Canada,
Europe, and Japan (8, 10, 28). Results of a serosurvey in the
United States (n = 1,556) demonstrate that infection is fairly
common in both clinic (5.2%) and sick (15.2%) cat popula-
tions (19). Several additional seroepidemiological surveys
have found similar infection rates (7, 10, 23, 27, 28).
A 24,000-dalton protein (p24) has been identified as an FIV
group-associated antigen and is the predominant core struc-
tural protein of the virus (R. Steinman, J. Dombrowski, T.
O'Connor, R. C. Montelaro, Q. Tonelli, K. Lawrence, C.
Seymour, J. Goodness, N. Pedersen and P. R. Andersen, J.
Gen. Virol., in press). The major core protein of FIV was
initially designated as p26; the nomenclature was derived
from the estimation of its molecular mass based on migration
in polyacrylamide gels. However, recent genetic sequence
data show that the molecular mass is approximately 24,000
daltons and indicate that the protein should be designated
p24 (25). In this report, we describe a microdilution plate-
based enzyme-linked immunosorbent assay (ELISA) for the
detection of FIV p24 antigen. The FIV-antigen ELISA is a
qualitative and quantitative test that can be used to detect
and monitor the growth of virus in tissue culture samples.
* Corresponding author.
The assay can be used to confirm the presence of virus in
tissue culture fluids following culturing of lymphocytes from
feline blood or tissue extracts.
MATERIALS AND METHODS
Virus and cell culture. FIV (Petaluma strain) was propa-
gated in chronically infected Crandell feline kidney (CRFK)
cells (3). The virus is noncytopathogenic for CRFK cells and
was concentrated from tissue culture fluids by precipitation
with polyethylene glycol (2) and purified by density gradient
centrifugation on glycerol gradients as described previously
(16). Purified feline leukemia virus was obtained from Elec-
tronucleonics (Fairfield, N.J.). Feline infectious peritonitis
virus (strain 79-1146) was obtained from the American Type
Culture Collection (Rockville, Md.).
Monoclonal antibody production. BALB/cJ mice (Jackson
Laboratory, Bar Harbor, Maine) were immunized with dis-
rupted FIV mixed with an equal volume of complete adju-
vant H37Ra (Difco Laboratories, Detroit, Mich.). Mice were
boosted 2 weeks later with the same antigen preparation in
incomplete adjuvant. Fusions with P3x63-Ag8.653 mouse
myeloma cells and immunized mouse spleen cells were
performed 3 days after the last injection (11, 12). Hybrid-
omas were grown in hypoxanthine-aminopterin-thymidine
medium and screened by using FIV-coated microdilution
plates (IDEXX Corp, Portland, Maine). The FIV antigen-
coated microdilution plates were prepared as described
previously (19).
Anti-FIV monoclonal antibody ELISA. The anti-FIV
monoclonal antibodies were purified by ammonium sulfate
precipitation followed by protein-A Sepharose chromatogra-
phy (Pharmacia, Inc., Piscataway, N.J.). Microdilution
wells were coated overnight with 200 ,ul of purified 2D4
immunoglobulin G (IgG; 7.5 ,ug/ml) at 3 to 5 °C. Wells were
washed with phosphate-buffered saline-0.05% Tween 20,
blocked with 1% bovine serum albumin in Tris buffer, and
dried. The purified 4F2 monoclonal antibody was conjugated
to horseradish peroxidase (HRPO; Boehringer Mannheim
Biochemicals, Indianapolis, Ind.) by the procedure initially
described by Nakane and Kawaoi (17).
Screening assay. Twenty microliters of lysis buffer contain-
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ing 5.0% Triton X-100 was added to microdilution wells
followed by the addition of 200 ,ul of test sample. Plates were
incubated for 2 h at room temperature, aspirated, and
washed (five times). Two hundred microliters of anti-FIV-
HRPO conjugate was added to microdilution wells, incu-
bated for 30 min (room temperature), aspirated, and washed
(five times). Two hundred microliters of substrate-chro-
mogen solution (0.05% tetramethylbenzidine, 0.02% hydro-
gen peroxide, phosphate-citrate buffer [pH 4.8]) was added
to microdilution wells and incubated for 30 min (room
temperature), and the reaction was terminated with 50 ,ul of
dilute hydrofluoric acid (1:200). Individual microdilution
well A650 values were determined spectrophotometrically.
Positive control (PC) and negative control (NC) reagents
were assayed on each microdilution plate to validate indi-
vidual assays and calculate the assay cutoff. The NC con-
tained 10% bovine serum albumin; the PC contained a
standardized level of disrupted FIV in 10% bovine serum
albumin. The screening assay cutoff was calculated by
adding 0.150 absorbance units to the mean A650 value of
duplicate NC assays. The difference between the A650 value
of the PC and the mean A650 value of the NC assays was
greater than 0.500 units, and the mean A650 of the NC was
less than 0.250 units for all valid assays. An experimental
NC sample consisting of the medium that was used to dilute
FIV was assayed and compared with the NC to determine
reagent compatibility. The A6,5 of the experimental negative
control sample was +0.1 absorbance units of the NC mean
A650 for all assays.
Confirmatory assay. The confirmatory assay incorporated
a sample preincubation step with feline polyclonal anti-FIV
antibody (blocking reagent). The rest of the assay was
performed as described above for the screening assay.
Reactive samples and the PC were each divided into two
200-pil portions and were treated individually with either 40
pil of sample diluent (aliquot A) or 40 ,ul of pooled anti-FIV
antibody positive sera (aliquot B). These were incubated for
15 min, and 200-pul samples were added to microdilution
wells and assayed as described above. The confirmatory test
cutoffwas calculated by adding 0.125 absorbance units to the
NC A650 value. In valid confirmatory assays, the A650 of the
PC minus the A650 of the NC was greater than or equal to
0.500 units and the A650 of the NC was less than 0.250 units.
In addition, the A650 value of the PC was reduced by greater
than 50%. A sample was confirmed positive if the A650 value
of the aliquot A sample was greater than the confirmatory
test cutoff and if the A650 value of the aliquot B sample was
reduced by 50% or more relative to the A650 value of the
aliquot A sample. It was necessary for the A650 value of the
aliquot A sample to be less than 2.0. Samples with A650
values of greater than 2.0 were diluted 1:10 and retested.
Additional assays and reagents. The protein concentration
ofpurified FIV samples was determined by the bicinchoninic
acid protein assay (Pierce Chemical Co., Rockford, Ill.) by
using bovine serum albumin as a standard. Polyacrylamide
gel electrophoresis in the presence of sodium dodecyl sulfate
was performed as described by Laemmli (13) by using 10%
polyacrylamide gels. Proteins were visualized by staining the
gels with Coomassie brilliant blue R-250 (Sigma Chemical
Co., St. Louis, Mo.) and amido black lOB (Bio-Rad Labo-
ratories, Richmond, Calif.). The relative content of p24 in
the purified FIV preparations was estimated by densitomet-
ric scanning of the Coomassie brilliant blue- and amido
black-stained polyacrylamide gels by using a scanning den-
sitometer (GS-300; Hoefer Scientific, San Francisco, Calif.)
and software package (Hoefer Scientific). The calculated p24
content of the FIV preparation was essentially equivalent
following Coomassie brilliant blue and amido black staining
and was not stain dependent. The p24-antigen serial dilution
panel was prepared in 20% bovine serum albumin following
disruption of FIV by heating (65°C, 1 h) FIV in the presence
of 0.5% sodium dodecyl sulfate.
The Western blot (immunoblot) protocol used in this study
was a modification of the procedure initially reported by
Towbin et al. (26) and has been described previously (19).
Goat anti-mouse HRPO conjugate (Accurate Chemical Co.,
Westbury, N.Y.) was used for assays of mouse monoclonal
antibodies.
Isolation and culturing of FIV. Peripheral blood lympho-
cytes (PBLs) were isolated by the Ficoll-Hypaque method
from 3 to 5 ml of heparinized feline blood. The PBLs were
suspended in culture medium at a final concentration of 0.5
x 10' to 1.0 x 106 cells per ml and placed in 25-cm2 culture
flasks. To this cell suspension, mitogen-stimulated normal
donor PBLs were added at normal donor to infected donor
PBL ratios of 1:1 or 1:2. The culture medium consisted of
RPMI 1640 with 10% heat-inactivated fetal bovine serum, 10
mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethane-
sulfonic acid), 100 U of penicillin per ml, 10 ,ug of strepto-
mycin per ml, 2 mM L-glutamine, 2 ,ug of polybrene per ml,
and 100 U of human interleukin-2 per ml. Cultures were
incubated in 5% CO2 at 37°C and monitored for syncytia
formation and other cytopathic effects. Culture supernatants
were harvested for reverse transcriptase (RT) activity as-
says, and cells were suspended in fresh culture medium
twice a week. These cultures were further supplemented
with mitogen-stimulated normal PBLs from the same donor
to maintain a minimum cell concentration of 0.5 x 106 to 1.0
x 106 cells per ml. Virus production was monitored by
syncytia formation and by an RT assay by using Mg2" as the
divalent cation, poly(rA)-oligo(dT2-18) as the template
primer, and a minimum of 5 ,uCi of IH]TTP per sample (22).
Solid tissue specimens were teased or minced aseptically
with forceps and scalpels and suspended in culture medium.
The procedure described for PBL samples was then followed
for the isolation of lymphocytes and the culturing of FIV.
Preparation of stimulated PBLs from normal cat donors.
Specific-pathogen-free (SPF) kittens and cats (Liberty Lab-
oratories, Liberty Corner, N.J.) were used as normal donors
of PBLs. Donor PBLs were prepared from heparinized
blood (5 to 40 ml) by the Ficoll-Hypaque method. The cells
were suspended in culture medium (not supplemented with
polybrene or human interleukin-2) and cultured in the pres-
ence of 5 ,ug of concanavalin A (ConA; Sigma) per ml in 5%
C02 at 37°C for 3 days. The stimulated donor PBLs were
then harvested, washed with sterile lx Hanks balanced salt
solution, and either suspended in complete culture medium
ready to be used for FIV isolation or suspended in culture
medium free of polybrene and recultured for later use.
RESULTS
Characterization of anti-FIV monoclonal and polyclonal
antibodies. The relative binding affinities of the FIV-reactive
monoclonal antibodies were compared by using FIV antigen-
coated microdilution wells and HRPO-conjugated goat anti-
mouse IgG. High-affinity antibodies were purified and used
to prepare antibody-coated microdilution wells and HRPO
conjugates. Matrix experiments were carried out by using
dilutions of inactivated FIV antigen to determine the optimal
assay configuration. Assay results for a single concentration
of FIV (10 ng/ml) obtained for six of the anti-FIV monoclo-
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TABLE 1. Optimization of assay configuration: ELISA results as
A650 values for anti-FIV monoclonal antibodies used as
conjugates and to coat microassay wells
Monoclonal A650 value for the following monoclonal
antibody- antibody-HRPO conjugatesc
coated
strip 6E6 5E2 2D4 3H8 4F2 4E10
6E6 0.135 0.417 0.096 0.125 0.385 0.338
5E2 0.996 0.140 0.373 0.072 0.118 0.136
2D4 1.021 0.817 0.061 0.830 1.994 1.532
3H8 0.831 0.121 0.250 0.069 0.111 0.101
4F2 0.981 0.223 0.305 0.072 0.159 0.121
4E10 0.759 0.216 0.313 0.068 0.156 0.103
a Assays were carried out at a single concentration of FIV antigen (10 ng/
mi).
b Microdilution wells were coated with 100 RI of each monoclonal antibody
at a concentration of 10 ,ug/ml.
C The concentration of each conjugate was 10 p.g/ml.
nal antibodies are shown in Table 1. Maximal test sensitivity
was achieved by using the 2D4 monoclonal antibody to coat
the microdilution wells and the 4F2 monoclonal antibody for
conjugate preparation.
The FIV subcomponent specificities of the 2D4 and 4F2
monoclonal antibodies were determined by preparing HRPO
conjugates and reacting each one with FIV Western blot
strips (Fig. 1). Strip A shows the assay result for an FIV
antibody-positive serum pool and delineates the positions of
FIV-reactive subcomponents (19). Assay results for the
2D4-HRPO and 4F2-HRPO conjugates (lanes D and E,
respectively, in Fig. 1) demonstrated that each is specific for
the p24 component of FIV. An ELISA was carried out to
A. B. C. D. E.
p55-. ,. a.:f
p32.
p24 >
FIG. 1. Western blot (immunoblot) assays of the anti-FIV-pos-
itive serum pool (lane A), negative control (lane B), FIV-blocking
reagent (lane C), and the anti-FIV-HRPO conjugates 2D4-HRPO
(lane D) and 4F2-HRPO (lane E). Feline samples were diluted
(1:100) in sodium phosphate buffer (pH 7.4) containing 30% calf
serum and incubated for 1 h with the lanes containing FIV. These
were washed, incubated with anti-feline-HRPO, washed again, and
reacted with H202 and 4-chloronaphthol. The anti-FIV-HRPO
monoclonal antibody conjugates were assayed in a similar fashion
with elimination of the anti-feline-HRPO conjugated reaction. gp4O,
Glycoprotein 40.
E
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FIG. 2. Monoclonal antibody epitope analysis. The relative bind-
ing of a constant concentration (10 p.g/ml) of 2D4-HRPO (O) and
4F2-HRPO (+) to an FIV antigen-coated microdilution well was
measured in the presence of various levels (0 to 100 ,ug/ml) of
unconjugated 2D4 (A) and 4F2 (B). OD, Optical density.
determine whether the 2D4 and 4F2 monoclonal antibodies
compete for binding to a single p24 epitope. The relative
binding of each HRPO conjugate to FIV-coated microdilu-
tion wells was measured in the presence of various levels of
unconjugated 2D4 and 4F2 (Fig. 2). The lack of competition
3.5
3.0
2.5
E
O
a
in
go
O
0
2.0
1.5
1.0
0.5
0.0
FIV p24 ng/mi
FIG. 3. FIV-antigen ELISA optical density (OD) values for
disrupted virus samples containing less than 5.0 ng of FIV p24 per
ml. Screening and confirmatory assays were conducted as described
in the text and had assay cutoff values of 0.221 and 0.196, respec-
tively. Symbols: W, screening; +, aliquot A; O, aliquot B.
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FIG. 4. The FIV endpoint titration experiment was conducted with 10-fold serial dilutions of an FIV-containing tissue culture fluid
prepared in uninfected tissue culture medium. The inoculum A6SO is the FIV-antigen ELISA result for each serial dilution prior to the initiation
of the cell culture. Experimental conditions are described in the text. OD, Optical density.
between 2D4-HRPO and 4F2 and between 4F2-HRPO and
2D4 indicates that the monoclonal antibodies react with
different epitopes of FIV.
The blocking reagent used in the confirmatory procedure
was a high-titer pool of feline anti-FIV positive sera. The
pooled reagent showed a strong reaction to the FIV-specific
proteins piS, p24, p32, gp40, p47, and p65 when tested by
the Western blot assay (Fig. 1, lane C). The blocking reagent
inhibited binding of both 2D4-HRPO and 4F2-HRPO to
FIV-coated microdilution wells when tested in a competition
ELISA (data not shown).
The monoclonal antibodies used in the FIV-antigen
ELISA showed no reaction when they were tested with
concentrated samples of feline leukemia virus or feline
infectious peritonitis virus. A dilution series of each virus
was prepared in fetal bovine serum and tested by virus-
specific assays and by the FIV-antigen ELISA. Dilutions of
feline leukemia virus (1:1,000 to 1:32,000) were positive by
the PetChek feline leukemia virus-antigen ELISA (IDEXX
Corp.), and dilutions of feline infectious peritonitis virus
(1:10 to 1:10,000) were positive in a tissue culture assay for
feline infectious peritonitis virus. Each of these samples was
negative when tested by the FIV-antigen ELISA (data not
shown).
Assay sensitivity. A p24 serial dilution panel (0.05 to 1,000
ng/ml) was prepared in 20%o bovine serum albumin as de-
scribed in Materials and Methods. The panel was tested by
the FIV-antigen ELISA by using both the screening and
confirmatory procedures. Results for samples containing
less than 5 ng of p24 per ml are represented in Fig. 3.
Samples containing greater than 5 ng/ml gave screening
assay A650 values of greater than 3.0 (data not shown). The
confirmatory diluent control A650 value (aliquot A) was
slightly less than the corresponding A650 value obtained in
the screening test and reflects the 1.2-fold sample dilution
that occurred following the addition of the confirmatory
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FIG. 5. The experimental infection temporal series was con-
ducted by inoculation of two SPF cats (HV1 [A] and IB2 [B]) with
blood from a confirmed FIV antibody-positive animal (Ch). Lym-
phocytes were obtained several times postinoculation and were
added to tissue culture medium. Tissue culture fluids were sampled
before and 14 days following stimulation of lymphocytes with conA.
Symbols: O, prestimulation; +, poststimulation.
reagent (Fig. 3). Both assays had a sensitivity limit of
approximately 0.2 ng of p24 per ml. Specific viral inhibition
(inhibition values of greater than 50%) was confirmed for
each panel member.
In a separate study, the sensitivity of the antigen-capture
ELISA was compared with that of the assay of viral RT
activity. Twofold serial dilutions of FIV were prepared in
FIV-negative tissue culture medium by using a tissue culture
sample containing untreated FIV. These were tested by the
FIV-antigen ELISA and by enzymatic assay of viral RT
activity. The assay cutoff for the FIV-antigen ELISA was
0.231 (NC + 0.150); the last serial dilution that was positive
by this assay was 1:25,600. The cutoff for the RT activity
assay (estimated to be twice the background corrected value
of the negative control mean counts per minute) was 1,427
cpm. The last serial dilution that was positive by the RT
activity assay was 1:3,200 (data not shown).
A series of experiments was conducted to determine the
endpoint dilution of an FIV culture and to estimate the
length of time required for detection of FIV antigen in tissue
culture. Tenfold serial dilutions of tissue culture fluid con-
taining FIV were prepared in uninfected tissue culture
medium. Samples of the dilution series (ranging from 1:10' to
1:106) were first assayed by the FIV-antigen ELISA and then
used to inoculate uninfected CRFK cultures at 50% conflu-
ency. Samples of tissue culture fluid were withdrawn daily
TABLE 2. ELISA detection of FIV antigen in CRFK cells
cocultivated with splenic lymphocytes derived
from an FIV-positive cat
Incubation time ELISA A6.5j % Inhibition(days)
0 0.158
7 0.602 84
15 2.641 96
20 1.529 95
a Assay cutoff, 0.258.
and tested for the presence of FIV by the FIV-antigen
ELISA.
2 Assay results for samples in the dilution series are repre-
sented by the individual graphs shown in Fig. 4. The
FIV-antigen ELISA result for each dilution sample prior to
infection of the CRFK culture is given above each graph.
The time needed to productively infect each CRFK culture
increased with the dilution of FIV. The 1:105 dilution sample
was the highest dilution panel member to productively infect
the CRFK culture. This required a 9-day incubation period.
Application of antigen-capture ELISA for the detection of
FIV infection. (i) SPF cats. Lymphocytes were isolated from
whole blood of four SPF cats (Sa, Sh, Si, and SI) and were
used to inoculate tissue culture medium as described in the
Materials and Methods. Tissue culture samples (0.2 ml) were
obtained 14 days after lymphocyte stimulation and were
assayed by the FIV-antigen ELISA. Each of the tissue
culture supernatants derived from the SPF cats was negative
for FIV antigen after 14 days (data not shown).
(ii) FIV antibody-positive cats. Blood samples from five
FIV antibody-positive field cats (Ot, Sc, Ch, Da, and St)
were obtained. These were positive by the PetChek FIV-
antibody ELISA (IDEXX Corp.) and were confirmed to be
positive by the FIV Western blot assay. Lymphocytes were
obtained from these samples, used to inoculate tissue culture
medium, and stimulated as described above. The tissue
culture fluids were sampled 14 days following inoculation
and assayed by the FIV-antigen ELISA. Each of the tissue
culture supernatants derived from the FIV antibody-positive
cats was positive after 14 days. All were confirmed to be
positive by the FIV-specific inhibition assay (data not
shown).
(iii) Temporal series. Two SPF cats (HV1 and IB2) were
inoculated (intraperitoneally) with whole blood (2.0 ml) from
one of the confirmed FIV-positive cats described above
(Ch). Samples of whole blood were obtained from the
experimentally infected cats (HV1 and IB2) before and at
several times after inoculation. Lymphocytes were isolated
from these whole blood samples and were added to the tissue
culture medium. The tissue culture fluids were sampled
before and 14 days following stimulation of lymphocytes
with ConA.
The FIV-antigen ELISA results for tissue culture samples
are presented in Fig. 5. All tissue culture samples obtained
prior to lymphocyte stimulation were negative. Lympho-
cytes derived from preinoculation blood samples failed to
produce detectable virus after 14 days, while all lympho-
cytes derived from postinoculation blood samples produced
high levels of virus after 14 days. Ail samples testing positive
by the screening assay were confirmed to be positive by the
confirmatory procedure. To demonstrate that the experi-
mentally infected animals had seroconverted following the
initial inoculation, serum samples from cats HV1 and IB2
were tested by the FIV-antibody ELISA (IDEXX Corp.).
A
Day 14 Post Con A Stimulation
Pre Con A Stimulation
;o~~~~~~~~~~~~~
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Both animals were positive for antibody to FIV by week 1
(data not shown).
(iv) Tissue sample. The spleen was obtained from a con-
firmed FIV antibody-positive cat (Ch). The tissue was ho-
mogenized and lymphocytes were isolated by density gradi-
ent centrifugation, as described in Materials and Methods.
These were cocultivated with CRFK cells, stimulated with
ConA, and incubated at 37°C for 20 days. Tissue culture
samples (0.2 ml) were obtained at several times as described
above and assayed by the FIV-antigen ELISA. The FIV-
antigen ELISA results are shown in Table 2. Spleen lym-
phocytes from the FIV-positive animal produced high levels
of virus in tissue culture after 7 days and throughout the
entire test period (20 days).
DISCUSSION
Results of the anti-FIV monoclonal antibody characteri-
zation experiments demonstrate that the 2D4 and 4F2 mono-
clonal antibodies are directed against different epitopes of
FIV p24 and are suitable for use in a sandwich ELISA. The
FIV-blocking reagent contains antibodies directed against
epitopes on p24 that are recognized by 2D4 and 4F2 and
block the binding of these monoclonal antibodies to p24. To
ensure that the potency of the blocking reagent was sufficient
to saturate potential monoclonal antibody-binding sites, the
maximum A650 value for the diluent-treated sample (aliquot
A) in the confirmatory assay was limited to 2.0. In a qualified
confirmation assay, aliquot A samples that gave optical
density values greater than 2.0 were diluted 1:10 and
retested.
The results of the FIV-antigen ELISA correlated with
measurements of RT enzymatic activity for untreated virus
in tissue culture samples. The FIV-antigen ELISA was three
twofold serial dilutions more sensitive than the assay for
viral RT activity. These results are consistent with similar
observations that were made when the sensitivities of the RT
assay and p24 antigen-capture ELISAs were compared for
the detection of human immunodeficiency virus type 1 in
tissue culture samples (14).
The endpoint titration experiment (Fig. 4) was performed
to determine the endpoint dilution for an FIV-containing
tissue culture sample and to measure the time course of virus
production in tissue culture medium. The time required to
produce detectable virus in tissue culture varied from 1 to 9
days and was proportional to the dilution of FIV in the initial
inoculum. The 1:105 dilution sample was the highest dilution
panel member to productively infect the CRFK culture. It is
noteworthy that this sample was negative (ELISA optical
density, 0.109) when it was tested by the FIV-antigen
ELISA prior to inoculation of the CRFK culture. The cell
culture step provided the amplification needed to produce a
measurable level of virus.
The FIV-antigen ELISA would be useful as a replacement
for RT activity assays for monitoring the growth of virus in
tissue culture and for monitoring the recovery of virus during
virus purification. The assay has application for use by
clinicians in the identification of presumptive virus-positive
specimens. Samples could be confirmed to be antigen posi-
tive by the FIV-antigen ELISA by culturing lymphocytes
from feline blood or tissue extracts and monitoring them for
the production of virus in tissue culture media.
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